CN111566089B - Ire1小分子抑制剂 - Google Patents

Ire1小分子抑制剂 Download PDF

Info

Publication number
CN111566089B
CN111566089B CN201880085863.XA CN201880085863A CN111566089B CN 111566089 B CN111566089 B CN 111566089B CN 201880085863 A CN201880085863 A CN 201880085863A CN 111566089 B CN111566089 B CN 111566089B
Authority
CN
China
Prior art keywords
amino
pharmaceutically acceptable
acceptable salt
chloro
ethylquinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880085863.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111566089A (zh
Inventor
J·P·瓦卡
D·李
S·贝蒂戈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN111566089A publication Critical patent/CN111566089A/zh
Application granted granted Critical
Publication of CN111566089B publication Critical patent/CN111566089B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880085863.XA 2017-11-10 2018-11-08 Ire1小分子抑制剂 Active CN111566089B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584575P 2017-11-10 2017-11-10
US62/584,575 2017-11-10
US201862678723P 2018-05-31 2018-05-31
US62/678,723 2018-05-31
PCT/US2018/059894 WO2019094641A1 (en) 2017-11-10 2018-11-08 Ire1 small molecule inhibitors

Publications (2)

Publication Number Publication Date
CN111566089A CN111566089A (zh) 2020-08-21
CN111566089B true CN111566089B (zh) 2023-11-17

Family

ID=64477302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880085863.XA Active CN111566089B (zh) 2017-11-10 2018-11-08 Ire1小分子抑制剂

Country Status (6)

Country Link
US (5) US10745379B2 (https=)
EP (1) EP3707126B1 (https=)
JP (3) JP7271538B2 (https=)
CN (1) CN111566089B (https=)
CA (1) CA3082363A1 (https=)
WO (1) WO2019094641A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS
CA3064837A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US10745379B2 (en) 2017-11-10 2020-08-18 Cornell University IRE1 small molecule inhibitors
EP3891137B1 (en) 2018-12-03 2024-10-09 Cornell University Ire1 small molecule inhibitors
WO2020232401A1 (en) * 2019-05-15 2020-11-19 Cornell University Combination therapies with ire1 small molecule inhibitors
WO2020252165A1 (en) * 2019-06-11 2020-12-17 Genentech, Inc. Quinazolinyl compounds and methods of use
JP2021031420A (ja) * 2019-08-21 2021-03-01 日東電工株式会社 Ｍｙｈ９の阻害物質を用いた、がん転移抑制
US20240262830A1 (en) * 2020-02-03 2024-08-08 Nimbus Iaso, Inc. Ire1a modulators and uses thereof
US11840523B2 (en) 2020-11-13 2023-12-12 The Regents Of The University Of California IRE1α inhibitors and uses thereof
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
CN114907350B (zh) * 2021-02-10 2023-12-29 上海凌达生物医药有限公司 一类含氮稠环类化合物、制备方法和用途
KR20240113496A (ko) 2021-12-03 2024-07-22 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물
EP4504720A4 (en) * 2022-04-08 2026-03-25 Alesta Therapeutics BV GCN2 MODULATOR COMPOUNDS
GB202207721D0 (en) 2022-05-25 2022-07-06 Cerevance Ltd Novel Compounds
AU2024356374A1 (en) * 2023-10-06 2026-04-16 Alesta Therapeutics BV Compounds of gcn2 modulators

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011127070A2 (en) * 2010-04-05 2011-10-13 Mannkind Corporation IRE-1α INHIBITORS
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016022839A1 (en) * 2014-08-06 2016-02-11 The Regents Of The University Of California Modulators of ire1
WO2017152117A1 (en) * 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2018222918A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US9422298B2 (en) 2011-03-17 2016-08-23 Cmg Pharmaceutical Co., Ltd. Pyridopyrimidine derivatives and use thereof
US10745379B2 (en) 2017-11-10 2020-08-18 Cornell University IRE1 small molecule inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047384A2 (en) * 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011127070A2 (en) * 2010-04-05 2011-10-13 Mannkind Corporation IRE-1α INHIBITORS
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
CN104995192A (zh) * 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016022839A1 (en) * 2014-08-06 2016-02-11 The Regents Of The University Of California Modulators of ire1
WO2017152117A1 (en) * 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
WO2018222918A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Also Published As

Publication number Publication date
CA3082363A1 (en) 2019-05-16
US20230271935A1 (en) 2023-08-31
US20190169160A1 (en) 2019-06-06
US10745379B2 (en) 2020-08-18
US10961218B2 (en) 2021-03-30
US20240425477A1 (en) 2024-12-26
US20220251065A1 (en) 2022-08-11
JP7271538B2 (ja) 2023-05-11
EP3707126A1 (en) 2020-09-16
CN111566089A (zh) 2020-08-21
WO2019094641A1 (en) 2019-05-16
EP3707126B1 (en) 2025-05-14
JP2023100744A (ja) 2023-07-19
US11634403B2 (en) 2023-04-25
US20200392106A1 (en) 2020-12-17
JP7535335B2 (ja) 2024-08-16
US12071424B2 (en) 2024-08-27
JP2024156774A (ja) 2024-11-06
JP2021502387A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
CN111566089B (zh) Ire1小分子抑制剂
US11649224B2 (en) IRE1 small molecule inhibitors
US20240165243A1 (en) Egfr degraders and methods of use
TW202116751A (zh) Ｈｐｋ１抑制劑及其用途
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
CN109843293A (zh) 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
TW201722957A (zh) 化學化合物
JP2025522354A (ja) 置換３，４－ジヒドロイソキノリン－１（２ｈ）－オン誘導体および関連する使用
WO2020232401A1 (en) Combination therapies with ire1 small molecule inhibitors
WO2020232403A1 (en) Treatment of fibrosis with ire1 small molecule inhibitors
WO2022213980A1 (zh) Tyk2抑制剂及其用途
TW201408672A (zh) □烷化合物
CN109476638B (zh) 吡唑衍生物、其组合物及治疗用途
WO2024233900A1 (en) Gsk3a inhibitors and methods of use thereof
WO2023274396A1 (zh) 苯并氮杂环类化合物及其在药物中的应用
HK40091563B (zh) 嘧啶酮类化合物及其用途
HK40091563A (zh) 嘧啶酮类化合物及其用途
WO2015027914A1 (zh) 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
HK40108258A (zh) (r)-戊二酰亚胺crbn配体和使用方法
HK40005135A (en) Pyrazole derivatives, compositions and therapeutic use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant